ArticleIBRO neuroscience reports2026
Serum amino acid levels are associated with brain hypometabolism in patients across the Alzheimer's disease continuum.
Article in IBRO neuroscience reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Alzheimer's disease (AD) is a multifactorial neurodegenerative disease. Identifying early diagnostic biomarkers are crucial for improving the accuracy and timeliness of the disease diagnosis and prognostication. Emerging evidence links metabolic dysregulation to AD pathogenesis. We evaluated serum metabolites and their association with regional brain hypometabolism measured using fluorodeoxyglucose positron emission tomography (FDG‑PET). Methods: We studied 892 participants using the Alzheimer's Disease Neuroimaging Initiative (ADNI) cohort, including 286 cognitively normal (CN) individuals, 468 patients with mild cognitive impairment (MCI), and 138 with AD who had a complete baseline FDG‑PET and serum metabolomics data. After outlier removal and adjustment for age, sex, and years of education, we tested linear associations between individual metabolite levels and glucose standardized uptake value ratio (SUVR) as a measure of brain metabolism within predefined regions of interest (ROIs). Results: In the AD group, higher levels of hydroxyproline (β = 0.24, P = 0.005) and aspartate (β = 0.17, P = 0.047) were associated with greater FDG SUVR prior to adjustment, although the association with aspartate did not remain significant after FDR correction. In the MCI group, higher levels of putrescine (β = -0.12, P = 0.010) and glutamine (β = -0.11, P = 0.019) were related to lower FDG SUVR prior to adjustment but lost significance after correction. In CN participants, higher levels of ornithine were associated with greater FDG SUVR (β = 0.13, P = 0.030) prior to adjustment. Conclusion: Our findings suggest that specific serum metabolites show differential associations with regional brain glucose hypometabolism in patients across the AD continuum. While these associations did not remain significant after correction for multiple testing, preliminary signals linking amino acid-related metabolites (e.g., hydroxyproline, aspartate, putrescine, glutamine, and ornithine) to brain metabolism highlight the potential role of metabolic pathways in AD pathophysiology. These results support the utility of metabolomics as a complementary approach for identifying early biomarkers of neurodegeneration.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.